PGY2 Pharmacy Residency Program Oncology Department of Pharmacy 622 West 168 th Street, VC-B New York, NY 10032 hp://www.nyp.org/pharmacy
PGY2 Pharmacy Residency Program Oncology
Department of Pharmacy 622 West 168th Street, VC-B
New York, NY 10032
http://www.nyp.org/pharmacy
NewYork-Presbyterian Hospital is the largest, not-for-profit, non-sectarian hospital in New York. With more than 2,600 beds, it provides state-of-the art inpatient, ambulatory, and preventive care in all areas of medicine at seven major centers: Weill Cornell Medical Center, Columbia University Irving Medical Center, Morgan Stanley Children's Hospital, Phyllis and David Komansky Center for Children's Health, Lower Manhattan Hospital, The Allen Hospital, and Westchester Division. As one of the largest and most comprehensive healthcare institutions in the world, NewYork-Presbyterian Hospital is committed to excellence in patient care, research, education, and community service. It ranks tenth on the U.S. News & World Report's guide to Best Hospitals. This academic medical center has affiliations with two of the nation's leading medical colleges: Weill Cornell Medical College and Columbia University Vagelos College of Physicians and Surgeons. NewYork-Presbyterian Hospital ranks 25th in cancer care on the U.S. News & World Report's guide to America's Best Hospitals with services in hematologic malignancies, solid tumors, and stem cell transplantation. In addition, the Herbert Irving Comprehensive Cancer Center is one of 68 National Cancer Institute (NCI) Designated Cancer Centers. The NCI designation recognizes “world-class, state-of-the-art programs in multidisciplinary cancer research.” At NewYork-Presbyterian Hospital we aim to provide PGY2 oncology pharmacy residents with the most comprehensive and advanced training possible. With our dedicated clinical specialists—including clinical pharmacists and world-renowned physicians—we ensure that our residents graduate from the program as competent and independent practitioners.
Khilna Patel, PharmD, BCOP Ambulatory Oncology Columbia University Irving Medical Center Email: [email protected]
PharmD: St. John’s University PGY1: North Shore University Hospital PGY2 (Oncology): NewYork-Presbyterian Hospital
Michelle Nguyen, PharmD, BCOP Medical Oncology Columbia University Irving Medical Center Email: [email protected]
PharmD: University of the Sciences in Philadelphia PGY1: Paoli Hospital PGY2 (Oncology): Roswell Park Cancer Institute
Maxwell A. Brown, PharmD Stem Cell Transplant Weill Cornell Medical Center Email: [email protected]
PharmD: Northeastern University School of Pharmacy PGY1: UPMC, Presbyterian Hospital PGY2 (Oncology): UPMC, Shadyside Hospital
Amrita Singh, PharmD Stem Cell Transplant Weill Cornell Medical Center Email: [email protected]
PharmD: St. John’s University PGY1: NewYork-Presbyterian Hospital PGY2 (Oncology): NewYork-Presbyterian Hospital
Christan Thomas, PharmD, BCOP Stem Cell Transplant Columbia University Irving Medical Center Email: [email protected]
PharmD: East Tennessee State University PGY1: NewYork-Presbyterian Hospital PGY2 (Oncology): NewYork-Presbyterian Hospital
Desiree Croteau, PharmD Leukemia Weill Cornell Medical Center Email: [email protected]
PharmD: Duquesne University PGY1: St. Joseph Medical Center PGY2 (Oncology): NewYork-Presbyterian Hospital
Ibis Lopez, PharmD, BCPS Pediatric Oncology Morgan Stanley Children’s Hospital of New York Email: [email protected]
PharmD: Rutgers, the State University of New Jersey PGY1: University of Kentucky PGY2 (Pediatrics): University of Kentucky
Jennifer Santamala, PharmD, BCOP Lymphoma Weill Cornell Medical Center Email: [email protected]
PharmD: University of the Sciences in Philadelphia PGY1: Lancaster General Hospital PGY2 (Oncology): NewYork-Presbyterian Hospital
Jessica Baron, PharmD, BCOP Lymphoma Columbia University Irving Medical Center Email: [email protected]
PharmD: Northeastern University PGY1: UMass Memorial Medical Center PGY2 (Oncology): MD Anderson Cancer Center
Hetal May, PharmD, BCOP Hematology/Oncology Operations And Investigational Drug Service Weill Cornell Medical Center Email: [email protected]
PharmD: Rutgers, the State University of New Jersey PGY1: University of Utah, Hospitals and Clinics PGY2 (Oncology): MD Anderson Cancer Center
Lillian Chou, PharmD, BCOP Hematology/Oncology Columbia University Irving Medical Center Email: [email protected]
PharmD: Rutgers, the State University of New Jersey PGY1: Grady Health System PGY2 (Oncology): MD Anderson Cancer Center
Cindy Ippoliti, PharmD Director of Oncology Pharmacy Services NewYork-Presbyterian Hospital Email: [email protected]
PharmD: University of the Sciences in Philadelphia Residency (Oncology): MD Anderson Cancer Center
Peter Campbell, PharmD, BCOP Leukemia Program Director, PGY2 Oncology Residency Columbia University Irving Medical Center Email: [email protected]
PharmD: St. John’s University PGY1: NewYork-Presbyterian Hospital PGY2 (Oncology): NewYork-Presbyterian Hospital
All residents are required to complete rotations in core subject areas
considered essential to providing a well-rounded experience. In addition,
a wide variety of elective rotations are offered allowing residents
flexibility in pursuing their individual areas of interest.
Required rotations
Solid Tumor Inpatient 4 weeks
Solid Tumor Outpatient 8 weeks
Leukemia 4 weeks
Lymphoma 4 weeks
Stem Cell Transplantation 4 weeks
Transplant Infectious Diseases 4 weeks
Investigational Drug Services 2 weeks
Palliative Care 2 weeks
Chemotherapy Compounding 2 weeks
Elective rotations
Total elective time: 8 weeks
Options:
- Benign Hematology
- Pediatric Oncology
- Any rotation may be repeated for an advanced elective
Required longitudinal experiences
Research Project
Medication Use Evaluation
Hematology/Oncology Subcommittee
Oncology Forum
Additional learning experiences include the development of teaching
skills by providing in-service presentations to pharmacy staff and other
health care providers, precepting PGY1 residents and pharmacy students,
leading case-based clinical discussions, and critically evaluating literature.
Meet Our Preceptors ———————————————————————–—————————
Curriculum ———————————————————————–—————————
The NewYork-Presbyterian Hospital (NYP) PGY2 residency program in
Oncology is a full-time post-graduate training program for practitioners
who desire to advance their knowledge and skills in oncology
pharmacotherapy. Our program is committed to providing residents with
the knowledge and skills necessary to become a capable pharmacy
practitioner. This involves intensive training in a wide variety of practice
settings with a diverse patient population that NYP is uniquely capable of
providing. The program is flexible and focuses on the goals of the
resident, but is intended to provide a well-rounded clinical, research, and
teaching experience.
PGY2 Pharmacy Residency Program in Oncology Duration: 12 months Positions: 2 Starting Date: July 1, 2019 Estimated Stipend: $51,500 Application Deadline: January 3, 2019 Interview Required: Yes Benefits Additional benefits include health, dental, and life insurance, sick leave, paid time off, and travel reimbursement for professional meetings. Residents also qualify for on-site subsidized housing, if available.
Admission to the residency program is available to PharmD graduates of
accredited colleges of pharmacy after completing a PGY1 residency program
(or equivalent). Residents must be United States citizens or carry a
permanent resident visa. New York licensure is required.
A limited (Intern) permit, issued by the office of Professions – New York State Board of Pharmacy, is necessary until licensure as a pharmacist in New York is obtained.
NYP Residency Programs participate in the ASHP-associated Pharmacy Online
Residency Centralized Application Service (PhORCAS). To apply for the
residency program, the following items must be submitted through PhORCAS
by the due date to be considered for an on-site interview:
Letter of intent stating goals and interests
Curriculum vitae
Three references in PhORCAS
Official college transcripts
For additional information, please contact:
Peter Campbell, PharmD, BCOP
Email: [email protected]
Rachel Abramova, PharmD PGY2 Pharmacy Resident, Hematology/Oncology NewYork-Presbyterian Hospital Email: [email protected]
PharmD: St. John’s University PGY1 (General): NewYork-Presbyterian Hospital
Stephanie Monaco, PharmD PGY2 Pharmacy Resident, Hematology/Oncology NewYork-Presbyterian Hospital Email: [email protected]
PharmD: University of Utah PGY1 (General): Veterans Affairs Salt Lake City Health System
Program Overview ———————————————————————–—————————
Application Requirements ———————————————————————–—————————
Current PGY2 Oncology Pharmacy Residents ———————————————————————–—————————
Employment Information ———————————————————————–—————————